BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19935706)

  • 1. Fhit regulates invasion of lung tumor cells.
    Joannes A; Bonnomet A; Bindels S; Polette M; Gilles C; Burlet H; Cutrona J; Zahm JM; Birembaut P; Nawrocki-Raby B
    Oncogene; 2010 Feb; 29(8):1203-13. PubMed ID: 19935706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression.
    Ji L; Fang B; Yen N; Fong K; Minna JD; Roth JA
    Cancer Res; 1999 Jul; 59(14):3333-9. PubMed ID: 10416589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL-induced apoptosis of FHIT-negative lung cancer cells is inhibited by FHIT re-expression.
    Mirandola P; Gobbi G; Sponzilli I; Malinverno C; Cavazzoni A; Alfieri R; Petronini PG; Vitale M
    J Cell Physiol; 2009 Aug; 220(2):492-8. PubMed ID: 19418484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells.
    Ishii H; Dumon KR; Vecchione A; Trapasso F; Mimori K; Alder H; Mori M; Sozzi G; Baffa R; Huebner K; Croce CM
    Cancer Res; 2001 Feb; 61(4):1578-84. PubMed ID: 11245468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of ectogenous FHIT gene on reversing malignant phenotype of human lung adenocarcinoma cells A549].
    Wang Y; Zhuo Q; Qin Y; Yuan S; Sun Z; Wang Y; Chen X; Sun Z; Song Y; Yang Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun; 19(3):225-9. PubMed ID: 12048684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line.
    Cavazzoni A; Petronini PG; Galetti M; Roz L; Andriani F; Carbognani P; Rusca M; Fumarola C; Alfieri R; Sozzi G
    Oncogene; 2004 Nov; 23(52):8439-46. PubMed ID: 15361849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ectogenous fragile histidine triad gene inhibits the malignant phenotype of human lung cancer cell line A549 in vitro and in vivo].
    Zhang LQ; Wang H; Lai BT; Yue WT; Zhan XP; Yang XH; Zhang CY; Zhang TM
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 May; 28(5):333-6. PubMed ID: 15949315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression.
    Roz L; Andriani F; Ferreira CG; Giaccone G; Sozzi G
    Oncogene; 2004 Dec; 23(56):9102-10. PubMed ID: 15489891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of fragile histidine triad expression in prostate carcinoma.
    Fouts RL; Sandusky GE; Zhang S; Eckert GJ; Koch MO; Ulbright TM; Eble JN; Cheng L
    Cancer; 2003 Mar; 97(6):1447-52. PubMed ID: 12627509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [FHIT--tumor suppressor protein involved in induction of apoptosis and cell cycle regulation].
    Pecherzewska R; Nawrot B
    Postepy Biochem; 2009; 55(1):66-75. PubMed ID: 19514467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression.
    Werner NS; Siprashvili Z; Fong LY; Marquitan G; Schröder JK; Bardenheuer W; Seeber S; Huebner K; Schütte J; Opalka B
    Cancer Res; 2000 Jun; 60(11):2780-5. PubMed ID: 10850413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer.
    Dumon KR; Ishii H; Vecchione A; Trapasso F; Baldassarre G; Chakrani F; Druck T; Rosato EF; Williams NN; Baffa R; During MJ; Huebner K; Croce CM
    Cancer Res; 2001 Jun; 61(12):4827-36. PubMed ID: 11406559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fragile histidine triad gene on biologic properties of muco-epidermoid carcinoma cells.
    Liu F; Wu JZ; Li F; Li Y; Li J
    Cytotherapy; 2008; 10(7):753-8. PubMed ID: 18985481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival.
    Capuzzi D; Santoro E; Hauck WW; Kovatich AJ; Rosato FE; Baffa R; Huebner K; McCue PA
    Cancer; 2000 Jan; 88(1):24-34. PubMed ID: 10618602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma.
    Yang Q; Yoshimura G; Suzuma T; Tamaki T; Umemura T; Nakamura M; Nakamura Y; Wang X; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2001 Dec; 7(12):3869-73. PubMed ID: 11751477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma.
    Kerr KM; MacKenzie SJ; Ramasami S; Murray GI; Fyfe N; Chapman AD; Nicolson MC; King G
    J Pathol; 2004 Jun; 203(2):638-44. PubMed ID: 15141378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites.
    Ishii H; Mimori K; Inageta T; Murakumo Y; Vecchione A; Mori M; Furukawa Y
    Mol Cancer Res; 2005 Mar; 3(3):130-8. PubMed ID: 15798093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis.
    Kitamura K; Hayashi K; Kobayashi R; Ishii H; Matsubayashi J; Matsumoto T; Suzuki M
    Oncol Rep; 2008 Apr; 19(4):847-52. PubMed ID: 18357366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
    Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
    Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.